Simplify Logo

Full-Time

Research Scientist

Analytical Development

Posted on 7/9/2024

Cerevel Therapeutics

Cerevel Therapeutics

201-500 employees

Develops treatments for neuroscience diseases

Biotechnology
Healthcare

Junior

Boston, MA, USA

Requires onsite presence in Boston, MA.

Category
Lab & Research
Life Sciences
Required Skills
Communications
Requirements
  • Strong analytical laboratory skills
  • Hands-on experience with analytical techniques such as HPLC, GC, titrations, spectroscopic techniques, and/or physical/solid form characterization
  • Knowledge of analytical method development, validation, and transfer principles and practices
  • Experience with laboratory software and systems such as ChemStation, MassHunter, and ELNs
  • Strong problem-solving, troubleshooting, and analytical skills
  • Excellent written and oral communication skills
  • Ability to work independently and collaboratively in a fast-paced and dynamic environment
Responsibilities
  • Perform analytical testing and characterization of drug substances and drug products
  • Develop, optimize, and validate analytical methods for drug substance and drug product characterization and control
  • Support method transfer and stability program design and execution for internal and external partners
  • Review and interpret analytical data and results, and communicate findings to cross-functional teams and senior management
  • Author and review analytical protocols, reports, and SOPs, and ensure compliance with cGMP and regulatory requirements
  • Support quality investigations and deviations, and implement corrective and preventive actions as needed
  • Identify and implement new and emerging technologies and best practices in analytical development

Cerevel Therapeutics develops new treatments for diseases related to the brain and nervous system. The company focuses on conditions like Parkinson's disease, epilepsy, and schizophrenia, using a combination of advanced chemistry and the study of how drugs interact with brain receptors. Unlike many competitors, Cerevel emphasizes a deep understanding of brain biology and neurocircuitry to guide its research and development efforts. The goal is to create effective therapies for the millions of people affected by these challenging diseases, with a commitment to rigorous evaluation and innovation in neuroscience.

Company Stage

IPO

Total Funding

$1.8B

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-51%

1 year growth

-46%

2 year growth

-41%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent Phase III success of tavapadon for Parkinson's disease demonstrates Cerevel's potential to bring impactful therapies to market.
  • The $8.7 billion acquisition by AbbVie underscores the high value and promise seen in Cerevel's neuroscience pipeline.
  • Strong financial backing and successful funding rounds ensure that Cerevel has the resources to continue its innovative R&D efforts.

What critics are saying

  • As a clinical-stage company, Cerevel faces the inherent risk of clinical trial failures, which could delay or derail product development.
  • The competitive landscape in neuroscience drug development is intense, with many companies vying for market share in areas like Parkinson's and Alzheimer's.

What makes Cerevel Therapeutics unique

  • Cerevel Therapeutics leverages a unique partnership with Pfizer and Bain Capital, providing a strong foundation in both scientific expertise and financial backing.
  • The company's focus on CNS receptor pharmacology and neurocircuitry sets it apart from competitors who may not have such specialized approaches.
  • Cerevel's pipeline includes potentially first-in-class therapies like tavapadon, which targets D1/D5 receptors to improve motor control in Parkinson's disease.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE